pharma · Hypovolemia · Pruritus, Chronic Kidney Diseases
Fresenius Kabi Australia
Fresenius Kabi Australia Pty Limited
Fresenius Kabi Australia is a pharma organization headquartered in Mount Kuring-Gai, AU. Primary therapeutic focus areas include Hypovolemia, Pruritus, Chronic Kidney Diseases, Chronic inflammatory diseases. NovaPharmaNe
Mount Kuring-Gai, AU HQ
150 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Mount Kuring-Gai, AU
- Employees
- 150
- Programs
- 5
- Drugs
- 6
- Patents
- 0
6% hydroxyethyl starch 130/0.4
Phase 3 · small molecule · Hypovolemia
6% hydroxyethyl starch 130/0.4 for Hypovolemia is a Phase 3 program (small_molecule) at Fresenius Kabi Australia Pty Limited with 1 ClinicalTrials.gov record(s).
Internal code HS-13-02-JP
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Fresenius Kabi Australia Pty Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hypovolemia
- Status
- completed
- Trials
- 1